Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E C Kohn
Combination Therapy: Intermittent Sorafenib With Bevacizumab Yields Activity and Decreased Toxicity
British Journal of Cancer
Cancer Research
Oncology
Related publications
Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Increased Antitumor Activity of Bevacizumab in Combination With Hypoxia Inducible Factor-1 Inhibition
Molecular Cancer Therapeutics
Cancer Research
Oncology
P3-027Liver Cirrhosis Associated With Paclitaxel and Bevacizumab Combination Therapy in a Metastatic Breast Cancer Patient
Annals of Oncology
Medicine
Oncology
Hematology
Toxicity of Locoregional Radiotherapy in Combination With Bevacizumab in Patients With Non-Metastatic Breast Cancer (TOLERAB): Final Long-Term Evaluation
PLoS ONE
Multidisciplinary
Gastric Cancer Combination Therapy: Synthesis of a Hyaluronic Acid and Cisplatin Containing Lipid Prodrug Coloaded With Sorafenib in a Nanoparticulate System to Exhibit Enhanced Anticancer Efficacy and Reduced Toxicity
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Alginate Hydrogel Improves Anti-Angiogenic Bevacizumab Activity in Cancer Therapy
European Journal of Pharmaceutics and Biopharmaceutics
Medicine
Biotechnology
Pharmaceutical Science
